Sooma Medical has secured €5 million in growth funding led by Voima Ventures to expand its innovative brain stimulation treatments for depression.

Target Information

Sooma Medical is a prominent provider of brain stimulation therapies aimed at treating psychiatric and neurological disorders, with a particular focus on depression. The company has announced a new round of growth funding amounting to €5 million, which was led by Voima Ventures, an early-stage investor known for its commitment to science-driven solutions. With this funding, Sooma seeks to enhance its efforts in making effective depression treatments more accessible worldwide, addressing a significant gap in mental health care.

Depression remains a leading cause of disability across the globe, with the World Health Organization reporting approximately 300 million individuals affected. Traditional treatment methods, such as antidepressants and psychotherapy, often come with limitations including suboptimal responses, adverse side effects, and restricted availability due to resources and lengthy wait times. In response, Sooma Medical is pioneering the use of Transcranial Direct Current Stimulation (tDCS) through its portable neuromodulation device, which provides a non-pharmaceutical option for alleviating depressive symptoms.

Industry Overview

The mental health industry in Finland, where Sooma Medical is based, is witnessing a crucial transformation, primarily driven by the increasing awareness and destigmatization of mental health issues. As the Finnish government acknowledges the rising prevalence of mental health disorders, there is a susta